KMT2A and leukemia: The VTP-50469 targets the expression of FLT3 by inhibiting leukemia transcription factor MEIS1 and promotes the loss of phosphorylated FLT3 mediated by FLT3 inhibitors, thus producing a synergistic antileukemia impact on NPM1mut or MLL-r leukemia [32] (Figure 2K).